Abbott (ABT) Initiates Absorb BVS vs. XIENCE PRIME Evaluation Trial

Abbott (NYSE: ABT) has initiated ABSORB II, the first randomized, controlled, multi-center clinical trial to evaluate the safety, efficacy and performance of the Absorb bioresorbable vascular scaffold (BVS) compared to the company's XIENCE PRIME Everolimus Eluting Coronary Stent System. Approximately 500 patients with coronary artery disease will be enrolled at about 40 investigational sites in Europe and New Zealand. The first patient was enrolled by Philip MacCarthy, M.D., consultant cardiologist and clinical lead, and Jonathan Hill, M.D., consultant cardiologist, at King's College Hospital in London.

Absorb is a bioresorbable scaffold designed to treat a patient's blocked vessel and then fully dissolve, leaving the vessel free of a permanent metallic implant. Because a permanent implant is not left behind, naturally occurring vessel functions may be restored. Absorb has CE Mark and is authorized for sale in Europe for the treatment of coronary artery disease. In the United States, Absorb currently is investigational and is not available for sale.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Abbott Labs (ABT) PT Raised to $135 at TD Cowen
• Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
• Nu Skin EVP of global sales takes medical leave